What can I expect from treatment for my moderate-to-severe AD?
Produced in collaboration with Asthma and Allergy Foundation of America.
Support for this patient education program was provided by Sanofi and Regeneron Pharmaceuticals.
Watch this interactive educational presentation designed to help people with atopic dermatitis (AD, also known as eczema) and caregivers.
The expert panel of clinicians, patients, and patient advocates also discusses the challenges patients from diverse racial and ethnic backgrounds encounter on their journey from AD diagnosis to long-term control.
Panelists discuss strategies to overcome those barriers and ensure access to care for AD and its related conditions. Patients and caregivers will be empowered to communicate treatment goals and preferences to their health care team and discuss the possibility of clinical trials as treatment options.
This presentation has the following learning objectives:
- Become involved in finding and accessing care for your eczema
- Understand the importance of people from diverse populations participating in clinical trials to ensure that innovative treatments work for everyone
- Talk with your doctor about the treatment plan for your AD and associated conditions that fits your needs and expectations and maintains long-term control
Among the topics discussed:
- Treatment for moderate-to-severe atopic dermatitis
- How to tell if treatment is working?
- Managing related type 2 (T2) conditions such as asthma
- What trials for T2 conditions exist
- Community resources
- How patient point of view affects treatment success
This program will also be helpful to anyone wanting to learn about clinical trials for atopic dermatitis.
Register to watch on demand.
What happens in AD, and why should it matter to me?
Is participation in a clinical trial for me?
Accessing care, and setting and maintaining goals for AD treatment: A panel discussion
Jonathan Silverberg, MD, PhD, MPH
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Jonathan Silverberg, MD, MPH, PhD, is a Professor of Dermatology at George Washington University School of Medicine and Health Sciences in Washington, DC and the Director of Clinical Research and Contact Dermatitis. Dr. Silverberg’s area of clinical subspecialty is inflammatory skin disease, particularly atopic and contact dermatitis. He has extensive experience in the advanced management of atopic dermatitis, contact dermatitis, hand eczema, chronic itch, psoriasis, hidradenitis and other chronic inflammatory skin disorders. Also, Dr. Silverberg is also a national expert in allergy patch testing, phototesting and photopatch testing. His research interests include the epidemiology of chronic and infectious diseases, and he has made major contributions to health services research and more.
Andrew Alexis, MD, MPH
Vice-Chair for Diversity and Inclusion
Department of Dermatology
Professor of Clinical Dermatology
Weill Cornell Medical College, Cornell University
Andrew Alexis, MD, MPH, is the Vice-Chair for Diversity and Inclusion for the Department of Dermatology and Professor of Clinical Dermatology at Weill Cornell Medical College in New York City. Currently, Dr. Alexis serves as President-Elect of the Skin of Color Society and is a member of the Board of Directors of the Scarring Alopecia Foundation. Having served as Director of the first-of-its-kind Skin of Color Center for over 15 years, his work has helped to advance patient care, research, and education pertaining to dermatologic disorders that are prevalent in populations with skin of color. Dr. Alexis has published more than 90 articles in peer-reviewed journals including the British Journal of Dermatology, Journal of the American Academy of Dermatology, and JAMA Dermatology.
Vice President, Corporate Affairs and Research
Asthma and Allergy Foundation of America
Sanaz Eftekhar, vice president of Corporate Affairs and Research at AAFA, leads tactical and strategic conversations with business partners and stakeholders across multiple industries. She has been instrumental in working with AAFA’s partners to present patient perspectives on the needs for atopic dermatitis treatments to the US Food and Drug Administration. In a greater effort to connect patients with vital clinical trials, Sanaz has been a key player in the development of AAFA’s upcoming clinical trial database. She has led AAFA’s involvement in the CIU & You campaign since its launch in 2015, co-authored several key AAFA research reports, and serves as secretary on the Board of Directors for the Global Allergy & Airways Patient Platform (GAAPP).
Parent of child with eczema